Real-world patient management practices in responders to venetoclax for newly diagnosed acute myeloid leukemia.
Ofir Wolach(Tel Aviv University), Aaron D. Goldberg(Memorial Sloan Kettering Cancer Center), Boaz Nachmias, Sameem Abedin(Medical College of Wisconsin), Rebecca Burne, Daniel A. Pollyea(University of Colorado Denver), Pankit Vachhani(University of Alabama at Birmingham), Joshua F. Zeidner(University of North Carolina at Chapel Hill), Yanqing Xu(AbbVie (United States)), Kendra Sweet(Moffitt Cancer Center), Catherine Lai(University of Pennsylvania), Evan Chris Chen(Dana-Farber Cancer Institute), Pinkal Desai(NewYork–Presbyterian Hospital), Lee Mozessohn(Sunnybrook Health Science Centre), Yakir Moshe(Tel Aviv University), Thomas W. LeBlanc(Duke University), Chia-Wei Lin, Marina Konopleva(Albert Einstein College of Medicine), Marin Xavier(Scripps Health), Tsila Zuckerman(Johannes Gutenberg University Mainz)
Cited by 0
Related Papers
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Cancer-Related Fatigue, Version 2.2015
|Journal of the National Comprehensive Cancer Network|2015|951
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
|New England Journal of Medicine|2020|859
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2017|655